Home › Funds › Invesco Ltd › GILD

Invesco Ltd position in GILD

GILEAD SCIENCES INC · Health Care

Invesco Ltd reported holding 38,662,436 shares of GILD (GILEAD SCIENCES INC) in its Q3 2026 13F filing — a position valued at US$5.76B, representing 0.47% of its reported portfolio and ranking #32 among its reported holdings. Invesco Ltd has disclosed GILD holdings in 21 of the last 21 reported quarters, going back to Q3 2021.

Latest position (Q3 2026)38.66M sh
Reported value held$5.76B
Portfolio Weight0.47%
First reportedQ3 2021
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Invesco Ltd's GILD position evolved

Invesco Ltd first disclosed a stake in GILD in Q3 2021 at 6,972,062 shares (US$487.0M). The position peaked in Q3 2026 at 38,662,436 shares, worth US$5.76B. Across 21 filings, Invesco Ltd increased the stake 13 time(s), trimmed it 7 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 38,662,436 shares valued at US$5.76B — a reduction of -1,156,715 shares quarter over quarter.. Notable position changes include a 34% increase in Q2 2025 (shares were roughly flat over the following quarter), a 84% increase in Q4 2025 (shares rose 14% over the following quarter), a 53% increase in Q2 2026 (shares rose 18% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2021 6.97M $487.00M New
Q4 2021 7.43M $539.33M Add
Q1 2022 7.70M $457.99M Add
Q2 2022 8.80M $543.79M Add
Q3 2022 9.22M $568.63M Add
Q4 2022 9.88M $848.50M Add
Q1 2023 10.17M $843.84M Add
Q2 2023 10.91M $840.84M Add
Q3 2023 10.36M $776.63M Reduce
Q4 2023 11.65M $943.67M Add
Q1 2024 11.28M $826.26M Reduce
Q2 2024 10.07M $690.74M Reduce
Q3 2024 9.99M $837.19M Reduce
Q4 2024 11.28M $1.04B Add
Q1 2025 10.13M $1.13B Reduce
Q2 2025 13.52M $1.50B Add
Q3 2025 15.14M $1.68B Add
Q4 2025 27.87M $3.42B Add
Q1 2026 26.05M $3.63B Reduce
Q2 2026 39.82M $5.03B Add
Q3 2026 38.66M $5.76B Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About GILD and 13F data

GILD (GILEAD SCIENCES INC) is a Health Care company. 33 other funds we track also report a position in GILD — the largest reported positions include Fidelity Management & Research (FMR) (US$8.68B), Capital World Investors (US$5.36B), Capital World Investors (US$5.18B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding GILD

All GILD fund holders →

FAQ

How long has Invesco Ltd held GILD?

Invesco Ltd has disclosed GILD holdings in 21 of the last 21 reported quarters, going back to Q3 2021.

What is Invesco Ltd's current position in GILD?

As of Q3 2026, Invesco Ltd holds 38.66M shares of GILD (GILEAD SCIENCES INC), valued at $5.76B, representing 0.47% of its reported portfolio and ranking #32.

Has Invesco Ltd been buying or selling GILD?

In the latest 13F filing (Q3 2026), Invesco Ltd reduced its position in GILD. The position peaked in Q3 2026 at 38.66M shares.

Which other funds hold GILD?

Other major institutional holders of GILD include Fidelity Management & Research (FMR), Capital World Investors, Capital World Investors, among 33 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.